A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2011
10/06/2011	US20110243981 Therapeutic myelin sheath derived antagonist peptide conjugates
10/06/2011	US20110243980 Methods and systems for o-glycosylating proteins
10/06/2011	US20110243979 Method of Transcutaneous Immunization Using Antigen
10/06/2011	US20110243978 Enterococcus antigens
10/06/2011	US20110243977 Surface proteins of streptococcus pyogenes
10/06/2011	US20110243976 Compositions comprising pneumococcal antigens
10/06/2011	US20110243975 Transformed soybean plant which accumulates vaccine, and use thereof
10/06/2011	US20110243974 Novel tumor antigen protein sart-3 and tumor antigen peptides thereof
10/06/2011	US20110243973 Hig2 and urlc10 epitope peptide and vaccines containing the same
10/06/2011	US20110243972 Prostate stem cell antigen vaccines and uses thereof
10/06/2011	US20110243971 Vaccines
10/06/2011	US20110243970 Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient
10/06/2011	US20110243969 Production of squalene from hyper-producing yeasts
10/06/2011	US20110243967 Molecular complexes which modify immune responses
10/06/2011	US20110243966 SINGLE CHAIN Fc (ScFc) REGIONS, BINDING POLYPEPTIDES COMPRISING SAME, AND METHODS RELATED THERETO
10/06/2011	US20110243965 Antibodies against domains of laminin-332
10/06/2011	US20110243964 Treatment of orthopedic conditions
10/06/2011	US20110243963 Antibodies to lrp6
10/06/2011	US20110243962 Therapeutic use of specific ligand in msrv associated diseases
10/06/2011	US20110243961 Methods for treating bone cancer by administering a nerve growth factor antagonist antibody
10/06/2011	US20110243960 Methods and compositions for treating p. acnes
10/06/2011	US20110243959 Modulating neuronal plasticity and treatment of neuronal loss by modulationg wnt7a or wnt7b modulation
10/06/2011	US20110243957 Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
10/06/2011	US20110243956 Methods of diagnosing and treating complications of pregnancy
10/06/2011	US20110243955 Antibody and uses thereof
10/06/2011	US20110243954 Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
10/06/2011	US20110243953 Neutralizing antibodies against gdf-8 and uses therefor
10/06/2011	US20110243952 Compound and method for regulating plasminogen activation and cell migration
10/06/2011	US20110243951 Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
10/06/2011	US20110243950 Msp2 antigenic peptides and their use
10/06/2011	US20110243949 Composition for producing anti-amyloid beta peptide antibodies with d-peptides
10/06/2011	US20110243948 Monoclonal Antibodies Against ANGPTL3
10/06/2011	US20110243947 Antibodies against csf-1r
10/06/2011	US20110243946 Remedies for pemphigus containing anti Fas ligand antibodies
10/06/2011	US20110243945 Anti-Inflammatory Agents
10/06/2011	US20110243944 Fusion Protein Inhibiting Osteoclast Formation, Preparation Method and Medicine Compositions Thereof
10/06/2011	US20110243943 Treatment using relaxin-fusion proteins with extended in vivo half-lives
10/06/2011	US20110243942 Relaxin-fusion proteins with extended in vivo half-lives
10/06/2011	US20110243941 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
10/06/2011	US20110243940 Bicyclic pyranone derivatives and methods of use thereof
10/06/2011	US20110243939 Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
10/06/2011	US20110243938 Methods to Reduce B-Helper T Cells to Treat Autoimmune Diseases
10/06/2011	US20110243937 Targeting pax2 for the treatment of breast cancer
10/06/2011	US20110243936 TNFalpha-NEUTRALIZING ANTIBODIES
10/06/2011	US20110243935 Compositions and Methods for Immunotherapy
10/06/2011	US20110243934 Epha3 antibodies for the treatment of multiple myeloma
10/06/2011	US20110243933 Perifosine and Capecitabine as a Combined Treatment for Cancer
10/06/2011	US20110243932 Anti-cd40 antibodies
10/06/2011	US20110243931 Combination therapy with type i and type ii anti-cd20 antibodies
10/06/2011	US20110243930 Compositions and methods for the treatment of immune related diseases
10/06/2011	US20110243929 Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
10/06/2011	US20110243928 Chimeric and humanised monoclonal antibodies against interleukin-13
10/06/2011	US20110243927 Methods of inhibiting tumor growth using beta 5 integrin antagonists
10/06/2011	US20110243926 Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
10/06/2011	US20110243925 Gene Expression Profiles Being Predictive for the Response of Tumors to Pharmaceutically Effective Compounds
10/06/2011	US20110243924 Novel methods
10/06/2011	US20110243923 Organic compounds
10/06/2011	US20110243922 Genetic Alterations Associated with Type I Diabetes and Methods of Use Thereof for Diagnosis and Treatment
10/06/2011	US20110243921 Prevention and treatment of cutaneous lupus erythematosus
10/06/2011	US20110243894 Methods of treating hepatitis c virus infection
10/06/2011	US20110243893 Markers for determination of patient responsiveness
10/06/2011	US20110243891 Dihydropyrazolopyrimidinone derivative
10/06/2011	US20110243889 Opioid and opioid-like compounds and uses thereof
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	US20110243841 Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
10/06/2011	US20110243840 Monoclonal antibodies against orthopoxviruses
10/06/2011	CA2795447A1 Epha3 antibodies for the treatment of multiple myeloma
10/06/2011	CA2795400A1 Prevention and treatment of cast nephropathy
10/06/2011	CA2795093A1 Immunogenic proteins and compositions
10/06/2011	CA2795081A1 Antibodies against csf-1r
10/06/2011	CA2795050A1 Method for preserving alum adjuvants and alum-adjuvanted vaccines
10/06/2011	CA2795047A1 Excipients for stabilising viral particles, polypeptides or biological material
10/06/2011	CA2795043A1 Humanized il-25 antibodies
10/06/2011	CA2795013A1 Stabilisation of viral particles
10/06/2011	CA2794851A1 Generation of antibodies to an epitope of interest
10/06/2011	CA2794674A1 Frizzled-binding agents and uses thereof
10/06/2011	CA2794631A1 Stabilized antibody preparations and uses thereof
10/06/2011	CA2794628A1 Stabilized antibody preparations and uses thereof
10/06/2011	CA2794499A1 Antibody-based depletion of antigen-presenting cells and dendritic cells
10/06/2011	CA2794407A1 Humanized anti cxcr4 antibodies for the treatment of cancer
10/06/2011	CA2794332A1 Anti-cd40 antibodies
10/06/2011	CA2794305A1 Compositions and methods for the removal of biofilms
10/06/2011	CA2793688A1 Monoclonal antibody directed against the p17 protein of hiv, capable of neutralising the binding of p17 to the p17 receptor (p17r)
10/06/2011	CA2793580A1 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
10/06/2011	CA2793139A1 Cross-species-specific psmaxcd3 bispecific single chain antibody
10/06/2011	CA2792537A1 Influenza virus vaccines and uses thereof
10/06/2011	CA2792174A1 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
10/06/2011	CA2698413A1 Rotavirus vaccine
10/05/2011	EP2371966A1 Recombinant lentiviral vector for expression of a Flaviviridae protein and applications thereof as a vaccine
10/05/2011	EP2371962A2 Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
10/05/2011	EP2371945A1 IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
10/05/2011	EP2371865A2 Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
10/05/2011	EP2371863A1 Humanized anti CXCR4 antibodies for the treatment of cancer
10/05/2011	EP2371862A2 Compositions monovalent for CD40L binding and methods of use
10/05/2011	EP2371861A1 Monoclonal antibodies against extracellular loops of C5aR
10/05/2011	EP2371859A2 Treatment of TNF alpha related disorders
10/05/2011	EP2371858A2 Human-Murine chimeric antibodies against respiratory syncytial virus
10/05/2011	EP2371854A2 Induction of tumor immunity by variants of folate binding protein
10/05/2011	EP2371849A1 Differential in tumour gene products and use of same
10/05/2011	EP2371848A1 Differential in tumour gene products and use of same

1 ... 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 ... 1823